2023 Chinese national clinical practice guideline on diagnosis and management of ulcerative colitis

作     者：Inflammatory Bowel Disease Group,Chinese Society of Gastroenterology,Chinese Medical Association Inflammatory Bowel Disease Quality Control Center of China Kaichun Wu Minhu Chen Jiaming Qian 

作者机构：不详 Xijing Hospital of Digestive DiseaseAir Force Medical UniversityXi’anShaanxi 710032China Department of Gastroenterologythe First Affiliated HospitalSun Yat-sen UniversityGuangzhouGuangdong 510080China Department of GastroenterologyPeking Union Medical College HospitalPeking Union Medical CollegeChinese Academy of Medical SciencesBeijing 100730China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2024年第137卷第14期

页      面：1642-1646页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：funded by the National Key R&D Program(No.2023YFC2507300) Guangdong R&D Program in Key Fields(No.2023B1111040003) 

主　　题：diagnosis clinical guideline 

摘      要：The role of Chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease(IBD)is *** clinical and basic research in China becomes standardized under a better understanding of IBD,more data on Chinese patients have become available to develop a consensus and *** guideline,collaboratively developed by the IBD Group,Chinese Society of Gastroenterology,incorporates the latest international consensus statements,[1-7]domestic research findings,and practical considerations,as an update based on the 2018 Chinese consensus on IBD management.[8]The IBD guideline consists of two parts:ulcerative colitis(UC)and Crohn’s disease,and this manuscript presented the UC *** evidence used in this guideline was collected and analyzed by the standard of guideline,and the contents were organized as problem statements,for *** formulation of this guideline aimed to reflect the latest progress in IBD,providing comprehensive and valuable guidance for the clinical management of IBD.